RU2019135261A3 - - Google Patents

Download PDF

Info

Publication number
RU2019135261A3
RU2019135261A3 RU2019135261A RU2019135261A RU2019135261A3 RU 2019135261 A3 RU2019135261 A3 RU 2019135261A3 RU 2019135261 A RU2019135261 A RU 2019135261A RU 2019135261 A RU2019135261 A RU 2019135261A RU 2019135261 A3 RU2019135261 A3 RU 2019135261A3
Authority
RU
Russia
Application number
RU2019135261A
Other languages
Russian (ru)
Other versions
RU2019135261A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019135261A publication Critical patent/RU2019135261A/ru
Publication of RU2019135261A3 publication Critical patent/RU2019135261A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2019135261A 2017-06-01 2018-05-30 Фармацевтическая композиция, содержащая ингибитор pde9 RU2019135261A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513690P 2017-06-01 2017-06-01
US62/513,690 2017-06-01
PCT/JP2018/020643 WO2018221546A1 (en) 2017-06-01 2018-05-30 Pharmaceutical composition comprising pde9 inhibitor

Publications (2)

Publication Number Publication Date
RU2019135261A RU2019135261A (ru) 2021-07-09
RU2019135261A3 true RU2019135261A3 (https=) 2021-09-08

Family

ID=64455959

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019135261A RU2019135261A (ru) 2017-06-01 2018-05-30 Фармацевтическая композиция, содержащая ингибитор pde9

Country Status (12)

Country Link
US (2) US11484502B2 (https=)
EP (1) EP3630113A4 (https=)
JP (1) JP7293129B2 (https=)
KR (1) KR20200010211A (https=)
CN (2) CN110545812A (https=)
AU (1) AU2018276566A1 (https=)
BR (1) BR112019023557A2 (https=)
CA (1) CA3059539A1 (https=)
MX (1) MX2019013198A (https=)
RU (1) RU2019135261A (https=)
SG (1) SG11201909359YA (https=)
WO (1) WO2018221546A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
SG10202113199RA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
CN120897742A (zh) * 2022-11-15 2025-11-04 福睿德姆生物科学公司 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效
CN119302958B (zh) * 2023-12-01 2025-10-21 郑州大学第一附属医院 含有bay 73-6691或其衍生物的药物制剂在制备治疗脑损伤疾病药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
EP0760819B1 (en) 1994-05-24 2000-07-19 F. Hoffmann-La Roche Ag Tricyclic dicarbonyl derivatives
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
AU2003250539A1 (en) 2002-08-07 2004-02-25 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
KR20080046728A (ko) 2005-09-15 2008-05-27 아스카 세이야쿠 가부시키가이샤 복소환 화합물, 그의 제조 방법 및 용도
WO2007146073A2 (en) 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
TW200808741A (en) 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
RS52166B (sr) 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
KR20110063447A (ko) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 피라졸로피리미딘 및 cns 장애의 치료를 위한 이들의 용도
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
MX2011009314A (es) 2009-03-05 2011-10-11 Astellas Pharma Inc Compuesto de quinoxalina.
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
CA2758321A1 (en) 2009-04-13 2010-10-21 Theravance, Inc. 5-ht4 receptor agonist compounds for treatment of cognitive disorders
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
EP2603511B1 (en) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
RS54834B1 (sr) 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
SI2573073T1 (sl) 2011-09-26 2015-02-27 Sanofi Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
JP5938299B2 (ja) 2011-10-05 2016-06-22 ダイセルポリマー株式会社 繊維強化樹脂組成物
JO3116B1 (ar) * 2011-10-07 2017-09-20 Eisai R&D Man Co Ltd مشتق بيرازولوكينولين كمثبطات ل pde9
US9573947B2 (en) * 2013-04-05 2017-02-21 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
JP2018515607A (ja) 2015-05-07 2018-06-14 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh 神経変性疾患を処置する組成物および方法
SG10202113199RA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제

Also Published As

Publication number Publication date
BR112019023557A2 (pt) 2020-06-02
JP7293129B2 (ja) 2023-06-19
CN110545812A (zh) 2019-12-06
EP3630113A1 (en) 2020-04-08
MX2019013198A (es) 2020-01-20
US20200078306A1 (en) 2020-03-12
CA3059539A1 (en) 2018-12-06
CN116585316A (zh) 2023-08-15
KR20200010211A (ko) 2020-01-30
EP3630113A4 (en) 2021-02-24
JP2020521726A (ja) 2020-07-27
US20220378706A1 (en) 2022-12-01
AU2018276566A1 (en) 2019-11-07
SG11201909359YA (en) 2019-11-28
US11484502B2 (en) 2022-11-01
RU2019135261A (ru) 2021-07-09
WO2018221546A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
BR122021024397A2 (https=)
BR122021000189A2 (https=)
BR112019008823A2 (https=)
BR112020006084A8 (https=)
BR122022025811B8 (https=)
BR202018014992U2 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003518A2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR102017023327A2 (https=)
BR202017021228U2 (https=)
BR202017020981U2 (https=)
BE2017C035I2 (https=)
BR202017017068U2 (https=)
BR202017016984U2 (https=)
BR202017016924U2 (https=)
BR102017015495A2 (https=)
BR102017015250A2 (https=)
BR102017014430A2 (https=)
BR202017012548U2 (https=)
BR202017011220U2 (https=)
BR202017010814U2 (https=)
BR202017010373U2 (https=)